Clinical Trial in Dogs

with Mammary Carcinoma, Squamous Cell Carcinoma, AGASACA, Melanoma and Histiocytic Sarcoma

Benefits and Participation

- Owners are financially responsible for the initial exam and screening tests to determine eligibility.
- Following the initial exam and screening, the remainder of this trial is funded for up to 2 months of treatment including tumor biopsy, recheck exams, bloodwork, and chemotherapy.
- Recheck visits for blood draws and monitoring are required and covered by the study.

Inclusion Criteria

- Diagnosis of mammary carcinoma, melanoma, squamous cell carcinoma, histiocytic sarcoma, or apocrine anal sac adenocarcinoma (AGASACA)
- Measurable tumor on physical exam
- Prior cancer treatment is allowed, but dogs must have cancer progression at the time of enrollment
- Pet must be otherwise healthy

Clinical Trial Background

- Cancer is ranked as the top cause of death in dogs.
- New anti-cancer therapies are desperately needed.
- Palbociclib is an oral chemotherapy drug used in various human cancers.
- Palbociclib has the potential to treat many canine cancers, however, the ideal dose has yet to be established in dogs.

Contact

Please direct any questions regarding the enrollment of a patient to the Auburn Oncology Service

Phone: (334) 844-4690
Email: onco@auburn.edu

AUBURN UNIVERSITY
College of Veterinary Medicine